Current Topics in Nonclinical Drug Development
Volume 2
1st Edition
Published on 9. November 2023
487 pages
978-1-000-96114-0 (ISBN)
Description
The second volume in the CURRENT TOPICS IN NONCLINICAL DRUG DEVELOPMENT SERIES explores the critical issues and current topics in nonclinical drug development. This second volume covers individual topics and strategies in drug development from compound characterization to drug registration. Written by a variety of experts in the field, recent and rapid advances in technologies and associated changes in regulatory guidance are discussed.
Select topics include:
Evolution of Artificial Intelligence (AI) technologies and the impact on toxicologic pathology.
Current approaches to carcinogenicity testing.
Predicting drug-drug interactions.
Current understanding of idiosyncratic drug reaction.
Assessing cardiovascular risks beyond QT interval.
Use of 3D cell cultures in toxicology and ADME.
Development of small molecule-antibody complexes.
Differentiating adverse from non-adverse findings in nonclinical studies.
Current Topics in Nonclinical Drug Development: Volume 2 will aid toxicologists, toxicologic pathologists, consultants, regulators, study directors, and nonclinical scientists dealing with day-to-day issues encountered in drug development and assist in formulating strategies for resolution of these issues. In addition, the book will be a valuable reference for academicians and graduate students pursuing research related to nonclinical drug development.
Select topics include:
Evolution of Artificial Intelligence (AI) technologies and the impact on toxicologic pathology.
Current approaches to carcinogenicity testing.
Predicting drug-drug interactions.
Current understanding of idiosyncratic drug reaction.
Assessing cardiovascular risks beyond QT interval.
Use of 3D cell cultures in toxicology and ADME.
Development of small molecule-antibody complexes.
Differentiating adverse from non-adverse findings in nonclinical studies.
Current Topics in Nonclinical Drug Development: Volume 2 will aid toxicologists, toxicologic pathologists, consultants, regulators, study directors, and nonclinical scientists dealing with day-to-day issues encountered in drug development and assist in formulating strategies for resolution of these issues. In addition, the book will be a valuable reference for academicians and graduate students pursuing research related to nonclinical drug development.
More details
Series
Edition
1. Auflage
Language
English
Place of publication
London
United Kingdom
Publishing group
Taylor & Francis Ltd
Target group
Professional and scholarly
Product notice
Reflowable
Illustrations
33 Tables, black and white; 18 Line drawings, color; 26 Line drawings, black and white; 21 Halftones, color; 1 Halftones, black and white; 39 Illustrations, color; 27 Illustrations, black and white
File size
16,09 MB
ISBN-13
978-1-000-96114-0 (9781000961140)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Philip Bentley | Pritam S. Sahota | Zbigniew Wojcinski
Current Topics in Nonclinical Drug Development
Volume 2
Book
11/2023
1st Edition
CRC Press
€289.00
Shipment within 15-20 days
Persons
Pritam S. Sahota, PhD, studied for his Veterinary Medicine (BVSc) and Veterinary Pathology (MVSc and PhD) degrees at Punjab Agricultural University in India. He is a Diplomate of the American Board of Toxicology. After completing his PhD, he immigrated to the USA in 1976 and worked for Dawson Research Corporation in Orlando, Florida for 10 years with increasing responsibilities as Toxicologic Pathologist, Senior Toxicologic Pathologist, and Scientific Director. Since 2012, Dr. Sahota has been President of Global ToxPath LLC (Toxicologic Pathology Consultancy) located in Kennewick, WA.
Philip Bentley, PhD, is Principal Consultant at Toxicodynamix International LLC. He studied biochemistry at the University of Hull, UK, graduating with a BSc in 1970 and a PhD in 1974. He had postdoctoral fellowships at the Universities of Basel. Switzerland and Mainz, Germany. He has authored more than 80 scientific publications, has lectured in toxicology at the University of Basel for more than 30 years, and is a past President of the European Society of Biochemical Pharmacology and the Swiss Society of Toxicology.
Zbigniew W. Wojcinski, DVM, DVSc is President of Toxicology & Pathology Consulting, LLC, in Hillsborough, NC and has over 35 years' experience in pharmaceutical drug development. Dr. Wojcinski earned his undergraduate degree (BSc) in Zoology from the University of Toronto and his DVM and DVSc (Pathology) degrees from the Ontario Veterinary College, University of Guelph. He is a certified Diplomate of the American Board of Toxicology and a Diplomate of the American College of Veterinary Pathologists.
Philip Bentley, PhD, is Principal Consultant at Toxicodynamix International LLC. He studied biochemistry at the University of Hull, UK, graduating with a BSc in 1970 and a PhD in 1974. He had postdoctoral fellowships at the Universities of Basel. Switzerland and Mainz, Germany. He has authored more than 80 scientific publications, has lectured in toxicology at the University of Basel for more than 30 years, and is a past President of the European Society of Biochemical Pharmacology and the Swiss Society of Toxicology.
Zbigniew W. Wojcinski, DVM, DVSc is President of Toxicology & Pathology Consulting, LLC, in Hillsborough, NC and has over 35 years' experience in pharmaceutical drug development. Dr. Wojcinski earned his undergraduate degree (BSc) in Zoology from the University of Toronto and his DVM and DVSc (Pathology) degrees from the Ontario Veterinary College, University of Guelph. He is a certified Diplomate of the American Board of Toxicology and a Diplomate of the American College of Veterinary Pathologists.
Content
1. Introduction and History of Digital Toxicologic Pathology 2. Carcinogenicity Testing of Human Pharmaceuticals 3. Differentiating Adverse and Non-adverse Findings in Nonclinical Studies 4. Current Understanding of Idiosyncratic Drug Reactions 5. Three-Dimensional Cell Culture Models in Toxicology and ADME 6. Assessing Cardiovascular Risk Beyond the hERG Channel and the QT Interval 7. Fundamentals of Drug-Drug Interactions 8. Development of Small Molecule-Antibody Complexes
